BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 126 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2017. The put-call ratio across all filers is 1.51 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $509,833 | -20.5% | 10,152 | 0.0% | 0.01% | -18.2% |
| Q2 2023 | $641,606 | +40.5% | 10,152 | 0.0% | 0.01% | +37.5% |
| Q1 2023 | $456,738 | +2.7% | 10,152 | 0.0% | 0.01% | -11.1% |
| Q4 2022 | $444,759 | -33.5% | 10,152 | 0.0% | 0.01% | -35.7% |
| Q3 2022 | $669,000 | +30.4% | 10,152 | 0.0% | 0.01% | +27.3% |
| Q2 2022 | $513,000 | -21.0% | 10,152 | 0.0% | 0.01% | -8.3% |
| Q1 2022 | $649,000 | -40.3% | 10,152 | 0.0% | 0.01% | -33.3% |
| Q4 2021 | $1,087,000 | +4.1% | 10,152 | 0.0% | 0.02% | -5.3% |
| Q3 2021 | $1,044,000 | +16.9% | 10,152 | 0.0% | 0.02% | +11.8% |
| Q2 2021 | $893,000 | -9.5% | 10,152 | 0.0% | 0.02% | -15.0% |
| Q1 2021 | $987,000 | -13.3% | 10,152 | 0.0% | 0.02% | -16.7% |
| Q4 2020 | $1,139,000 | +10.2% | 10,152 | -9.0% | 0.02% | 0.0% |
| Q3 2020 | $1,034,000 | +18.9% | 11,152 | 0.0% | 0.02% | +9.1% |
| Q2 2020 | $870,000 | +33.4% | 11,152 | 0.0% | 0.02% | +15.8% |
| Q1 2020 | $652,000 | -27.0% | 11,152 | 0.0% | 0.02% | -9.5% |
| Q4 2019 | $893,000 | +9.0% | 11,152 | 0.0% | 0.02% | 0.0% |
| Q3 2019 | $819,000 | -22.1% | 11,152 | 0.0% | 0.02% | -25.0% |
| Q2 2019 | $1,052,000 | +64.4% | 11,152 | +39.4% | 0.03% | +64.7% |
| Q1 2019 | $640,000 | +48.5% | 8,000 | 0.0% | 0.02% | +30.8% |
| Q4 2018 | $431,000 | -30.9% | 8,000 | 0.0% | 0.01% | -27.8% |
| Q3 2018 | $624,000 | +22.8% | 8,000 | 0.0% | 0.02% | +20.0% |
| Q2 2018 | $508,000 | -30.8% | 8,000 | 0.0% | 0.02% | -34.8% |
| Q1 2018 | $734,000 | +21.7% | 8,000 | 0.0% | 0.02% | +27.8% |
| Q4 2017 | $603,000 | -17.3% | 8,000 | -23.6% | 0.02% | -18.2% |
| Q3 2017 | $729,000 | +15.3% | 10,468 | -16.0% | 0.02% | +15.8% |
| Q2 2017 | $632,000 | +54.1% | 12,468 | +21.5% | 0.02% | +46.2% |
| Q1 2017 | $410,000 | +86.4% | 10,265 | +30.9% | 0.01% | +85.7% |
| Q4 2016 | $220,000 | -5.6% | 7,843 | 0.0% | 0.01% | -12.5% |
| Q3 2016 | $233,000 | – | 7,843 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 2,278,459 | $60,015,000 | 10.23% |
| Casdin Capital, LLC | 412,500 | $10,865,000 | 9.60% |
| Boxer Capital, LLC | 313,626 | $8,261,000 | 7.13% |
| Opaleye Management Inc. | 275,000 | $7,244,000 | 3.03% |
| RA Capital Management | 878,348 | $23,136,000 | 2.29% |
| PFM Health Sciences, LP | 1,008,232 | $26,557,000 | 0.81% |
| Perceptive Advisors | 404,404 | $10,652,000 | 0.79% |
| Partner Investment Management, L.P. | 18,052 | $475,000 | 0.78% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 680,160 | $17,915,000 | 0.60% |
| Redmile Group, LLC | 276,687 | $7,288,000 | 0.54% |